Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20337417 | 1.00 | BTK (0.34) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL23028470 | 0.88 | CTSK (0.34) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL22798665 | 0.85 | BTK (0.37) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL18321912 | 0.85 | BTK (0.37) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL18838482 | 0.85 | CTSK (0.38) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL18838439 | 0.85 | CTSK (0.38) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL22799108 | 0.84 | BTK (0.36) | BTKHSD11B1CTSKCYP2C9CA1 | |
| SCHEMBL28445812 | 0.82 | BTK (0.34) | BTKEPHX2MEN1MAPK1KMT2A | |
| SCHEMBL18328497 | 0.82 | BTK (0.34) | BTKEPHX2MEN1MAPK1KMT2A | |
| SCHEMBL18330207 | 0.81 | KDM1A (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3310771-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN3, PTPN1, PTPN2 | BTK 51/4885HSD11B1 958/4885CTSK 4077/4885 |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN5 | BTK 68/4885HSD11B1 1424/4885CTSK 4197/4885 |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | BTK 80/4885HSD11B1 1399/4885CTSK 4102/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | BTK 51/4885HSD11B1 958/4885CTSK 4077/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | BTK 70/4885HSD11B1 1939/4885CTSK 3479/4885 |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | BTK 70/4885HSD11B1 1939/4885CTSK 3479/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | BTK 68/4885HSD11B1 1390/4885CTSK 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.